42 results
8-K
EX-1.1
TRML
Tourmaline Bio Inc
26 Jan 24
Other Events
4:12pm
and in connection with the transactions contemplated hereby, including without limitation: (i) all expenses incident to the issuance and delivery
8-K
EX-99.2
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
to increase in connection with our ongoing activities as described in greater detail below. We are subject to all the risks incident in the development
8-K
EX-99.1
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
estimate that 15,000 to 20,000 patients out of the incident population in the United States have moderate to severe, active, inflammatory TED that may
424B3
vlncefv08
15 Sep 23
Prospectus supplement
6:31am
S-4/A
kwac6vq5 wtqlq6
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
EX-10.6
w5ati8utovw1ef5
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
S-4
EX-3.3
uhw3f 41q
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
S-4
4audk9p99q
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
425
hfbopo7m p0hamhz7s81
22 Jun 23
Business combination disclosure
9:12am
8-K
EX-2.1
hknr2rl
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am
S-3
EX-1.2
fsf0 vrufrse8i
15 Aug 22
Shelf registration
5:06pm